Notman Donald

Avg. Two Year Performance

23% Avg. Purchase Return
11% Compound
No sale track record
1 Mo3 Mo6 Mo1 Yr2 Yr
Average Purchase Return7%(3%)(20%)(8%)23%
Purchase Success Rate3 of 32 of 31 of 32 of 32 of 3
Average Sale Return----------
Sale Success Rate----------

Ocular Therapeutix, Inc

Drugs » Biotechnology

Chief Financial Officer:

Holdings: 195.36K shares

Sentiment

Insider Trading Sentiment: Accumulate

Avg. Two Year Performance

No purchase track record
No sale track record

Last Three Months:

0 Net Amount
Buy:0--
Sell:0--